

**Clinical Study of the WoundCare360 SiteSeal Adjunctive
Compression Device Following Interventional Endovascular
Procedures – NCT03234894**

Informed Consent Form:

Document Date: April 23, 2015



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____

DOB _____ (mm/dd/yyyy)

Patient Initials: _____

Visit Date: _____ (mm/dd/yyyy)

Eligibility

Please enter responses in space provided.

1. Has this patient met all eligibility criteria according to the protocol?
 - a. YES NO

Inclusion Criteria *All must be "YES" to qualify.*

| | | |
|--|-----|----|
| Is patient's age between 19 to 90? | YES | NO |
| Has patient given written informed consent for participation prior to the procedure? | YES | NO |
| Is this procedure an interventional procedure? | YES | NO |
| Is patient willing to undergo all study procedures and adhere to data collection and follow-up requirements? | YES | NO |
| Is patient a candidate for elective, non-emergent cardiac or peripheral vascular catheterization from the femoral artery approach? | YES | NO |
| Is patient willing to have a pre/post procedure ultrasound? | YES | NO |

Exclusion Criteria *All must be "NO" to qualify.*

| | | |
|---|-----|----|
| Is patient's age < 19 years? | YES | NO |
| Is patient's age > 90 years? | YES | NO |
| Did the patient receive GP IIb/IIIa inhibitors? | YES | NO |
| Is patient able to provide written informed consent on his/her own behalf? | YES | NO |
| Is patient unable or unwilling to adhere to data collection and follow-up requirements? | YES | NO |
| Is the procedure emergency PCI? | YES | NO |
| Is the patient on dialysis? | YES | NO |
| Does the patient have a known diagnosis of fibromyalgia? | YES | NO |



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____

DOB _____ (mm/dd/yyyy)

Patient Initials: _____

Visit Date: _____ (mm/dd/yyyy)

| | | |
|--|-----|----|
| Does the patient have acute coronary syndrome (i.e., unstable angina or myocardial infarction) \leq 48 hours before this catheterization procedure? | YES | NO |
| Was the patient's systolic blood pressure $<$ 90 mm Hg at the end of this catheterization procedure? | YES | NO |
| Is the patient immunocompromised? | YES | NO |
| Does the patient have pre- existing systemic infection or local infections at this access site? | YES | NO |
| Is the patient known or suspected to be pregnant, or is lactating? | YES | NO |
| Has the patient undergone prior or recent use of an intra- aortic balloon pump through the arterial access site? | YES | NO |
| Has the patient undergone prior vascular closure device use in the ipsilateral common femoral artery \leq 30 days before this catheterization procedure? | YES | NO |
| Has the patient undergone prior use of manual or mechanical compression for closure in the ipsilateral common femoral artery \leq 30 days before this catheterization procedure? | YES | NO |
| Did the patient require a re- puncture at a site previously punctured within 48 hours of this catheterization procedure? | YES | NO |
| Did the patient have an antegrade puncture in this catheterization procedure? | YES | NO |
| Did the patient have a puncture site believed to be in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries in this catheterization procedure? | Yes | NO |
| Was the patient's puncture tract angle $>$ 55° in this catheterization procedure? | YES | NO |
| Is the patient suspected to have experienced a femoral artery back wall puncture or who underwent $>$ 1 femoral artery puncture during this catheterization procedure? | YES | NO |



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____

DOB _____ (mm/dd/yyyy)

Patient Initials: _____

Visit Date: _____ (mm/dd/yyyy)

| | | |
|--|-----|----|
| Does the patient have significant anemia (hemoglobin < 10 g/dL, Hct < 30%)? | YES | NO |
| Does the patient have a known bleeding disorder, including thrombocytopenia (platelet count < 100,000 cells/ μ L), thrombasthenia, hemophilia, or von Willebrand's disease? | YES | NO |
| Did the patient have systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at the end of this catheterization procedure, unless systolic and/or diastolic pressure was lowered by pharmacological agents prior to the end of this catheterization procedure? | YES | NO |
| Did the patient have a baseline INR > 1.5 (e.g., on warfarin therapy)? | YES | NO |
| Was the patient's ACT > 300 seconds at the end of this catheterization procedure? | YES | NO |
| Did the patient undergo administration of low molecular weight heparin (LMWH) within 8 hours of this catheterization procedure? | YES | NO |
| Is continued heparin or other anticoagulant/antiplatelet therapy planned for this patient (with the exception of glycoprotein IIb/IIIa inhibitor therapy) during the first few hours following this catheterization procedure? | YES | NO |
| Did the patient have a complication or complications at the femoral artery access site during the catheterization procedure including bleeding, hematoma, intraluminal thrombus, pseudoaneurysm, or arteriovenous fistula? | YES | NO |
| Does the patient have an ipsilateral or bilateral lower extremity amputation(s)? | YES | NO |
| Is the patient known to require extended hospitalization (e.g., patient is undergoing cardiac surgery)? | YES | NO |



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____

DOB _____ (mm/dd/yyyy)

Patient Initials: _____

Visit Date: _____ (mm/dd/yyyy)

| | | |
|---|-----|----|
| Does the patient have a planned endovascular procedure within the next 30 days after this catheterization procedure? | YES | NO |
| Is the patient currently participating in another investigational study that has not concluded the follow-up period? | YES | NO |
| Has the patient already participated in this IDE study? | YES | NO |
| Is it known that the patient cannot adhere to or complete the study for any reason including but not limited to geographical residence or life-threatening disease? | YES | NO |

Signature _____

Date (mm/dd/yyyy) _____



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____ DOB _____ (mm/dd/yyyy)

Patient Initials: _____ Visit Date: _____ (mm/dd/yyyy)

Demographics

1. Date of Birth: _____ (dd/mm/yyyy)
2. Gender: MALE FEMALE
3. Race
 - a. Caucasian
 - b. Hispanic
 - c. Asian
 - d. Black
 - e. Other
4. Height: _____ (ft/inches)
5. Weight: _____ (lbs)
6. BMI: _____

Procedure-Related Data

1. Procedure Type:
 - a. CARDIAC PERIPHERAL VASCULAR
2. Access Site Location
 - a. RIGHT LEFT
3. Size of the introducer sheath:
 - a. _____ Fr.
4. Intra-procedure anticoagulants:
 - a. _____
5. Intra-procedure antiplatelet agents:
 - a. _____
6. Previous arterial puncture site in the ipsilateral common femoral artery >30 days before this catheterization procedure:
 - a. YES NO
7. Systolic blood pressure
 - a. _____ mm Hg



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____ DOB _____ (mm/dd/yyyy)

Patient Initials: _____ Visit Date: _____ (mm/dd/yyyy)

8. Diastolic blood pressure:
 - a. _____ mm Hg
9. Peripheral arterial disease:
 - a. YES NO
10. Activated clotting time (ACT) at the end of this catheterization procedure:
 - a. _____ seconds
11. Pre-procedural anticoagulants:
 - a. _____
12. Pre-procedure antiplatelet agents (including GP IIb/IIIa inhibitors):
 - a. _____
13. Post-procedural GP IIb/IIIa inhibitors
 - a. _____

MEDICATION HISTORY

PREVIOUS DIAGNOSTIC/INTERVENTIONAL ENDOVASCULAR PROCEDURES



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____ DOB _____ (mm/dd/yyyy)

Patient Initials: _____ Visit Date: _____ (mm/dd/yyyy)

Catheterization Procedure Data

1. Procedure Date: _____ (mm/dd/yyyy)
2. Pre-procedure Duplex Ultrasound?
 - a. YES NO
3. Procedure Start Time:
 - a. _____ (24hour)
4. Procedure End Time:
 - a. _____ (24hour)
5. Post procedure Duplex Ultrasound?
 - a. YES NO
6. Time of SiteSeal removal:
 - a. _____ (24hour)
7. Calculated time to deploy device without visible bleeding at the access site (TTH):
 - a. _____
8. Time of first standing & walking 20ft without evidence of arterial re-bleeding from the access site (TTA):
 - a. _____ (24hour)
9. Calculated Time To Ambulation (TTA):
 - a. _____ (24hour)
10. Adverse events:
 - a. YES NO
 - b. _____
11. Patient Discomfort:
 - a. Patient discomfort @ discharge from the catheterization lab:
 - i. _____ Patient comfort level (1-10) with 10 being intense pain
 - b. Patient discomfort @ 24 hours after this procedure:
 - i. _____ Patient comfort level (1-10) with 10 being intense pain



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____ DOB _____ (mm/dd/yyyy)

Patient Initials: _____ Visit Date: _____ (mm/dd/yyyy)

Primary Post Procedure Endpoints

1. Nerve Puncture

- a. Was there an involuntary leg muscle contraction and an auditory response at the time of placing the device?
 - i. YES NO

2. Femoral Artery Laceration

- a. Was there common femoral artery laceration (or needle penetration) with resultant bleeding or hematoma > 6 cm diameter?
 - i. YES NO

Secondary Endpoints

Major Complications @ 30day follow-up

1. Vascular repair or the need for vascular repair (via surgery, ultrasound-guided compression, transcatheter embolization, or stent-graft) – Y N
2. Access site-related bleeding requiring transfusion – Y N
3. Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram - Y N
4. Surgery or the need for surgery for access site-related nerve injury – Y N
5. Permanent (lasting > 30 days) access site-related nerve injury – Y N
6. Access site-related infection requiring intravenous antibiotics and/or extended hospitalization – Y N



Site Seal Adjunctive Compression Device

Protocol: 15-003 April 23, 2015

Woundcare 360
10900 S. Clay Blair Blvd.
Olathe, KS 66061

Patient ID: _____

DOB _____ (mm/dd/yyyy)

Patient Initials: _____

Visit Date: _____ (mm/dd/yyyy)

Minor Complications @ 30day Follow-up

1. Non-treated pseudoaneurysm documented by ultrasound – Y N
2. Non-treated arteriovenous (AV) fistula documented by ultrasound – Y N
3. Pseudoaneurysm treated with ultrasound-guided thrombin injection or ultrasound-guided fibrin adhesive injection – Y N
4. Access site hematoma greater than or equal to 6 cm – Y N
5. Access site-related bleeding requiring greater than 30 minutes to achieve hemostasis – Y N
6. Late (following hospital discharge) access site-related bleeding – Y N
7. Ipsilateral lower extremity arterial emboli – Y N
8. Transient loss of ipsilateral lower extremity pulse – Y N
9. Ipsilateral deep vein thrombosis – Y N
10. Access site-related vessel laceration – Y N
11. Transient access site-related nerve injury – Y N
12. Access site wound dehiscence – Y N
13. Localized access site infection treated with intramuscular or oral antibiotics – Y N